Загрузка страницы

Current status and future perspectives in immunotherapy for glioblastoma

Olivia Rongze Lu, PhD, University of Texas at Austin and Dell Medical School, Austin, TX, gives us an update on the current immunotherapeutic landscape for glioblastoma and outlines promising ongoing clinical trials, highlighting challenges in the development of effective immunotherapies for glioblastoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Видео Current status and future perspectives in immunotherapy for glioblastoma канала VJOncology
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
28 января 2022 г. 14:47:17
00:02:44
Другие видео канала
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BCEV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUCEV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUCSafety and preliminary evidence for efficacy for propranolol + pembrolizumab in metastatic melanomaSafety and preliminary evidence for efficacy for propranolol + pembrolizumab in metastatic melanomaOPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancerOPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancerAMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimabAMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimabReal-world toxicities associated with lorlatinib in ALK+ NSCLCReal-world toxicities associated with lorlatinib in ALK+ NSCLCWhat to do in patients with early-stage TNBC who have not achieved a pCR?What to do in patients with early-stage TNBC who have not achieved a pCR?Bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivityBevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivityReal-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UCReal-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UCCurrent treatment recommendations and future directions for EGFR-mutant NSCLCCurrent treatment recommendations and future directions for EGFR-mutant NSCLCDoes every patient with localized muscle-invasive bladder cancer need a cystectomy?Does every patient with localized muscle-invasive bladder cancer need a cystectomy?The future of immunotherapy in melanomaThe future of immunotherapy in melanomaIdentifying who requires a CT scan in staging for brain tumorsIdentifying who requires a CT scan in staging for brain tumorsBias and microaggressions in healthcareBias and microaggressions in healthcareUpcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Challenges of desmoid tumorsChallenges of desmoid tumorsExciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancerExciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancerVEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancerVEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancerKidney cancer: post-surgery sorafenibKidney cancer: post-surgery sorafenibHighlighting problems in personalized medicineHighlighting problems in personalized medicineLiposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTCLiposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC
Яндекс.Метрика